SCHEMBL3460769

SCHEMBL3460769

Nc1ncc(-c2cccc(C(=O)NCc3ccccc3)c2)nc1C(=O)NCCCNC(=O)c1ccco1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 12/20 0.53
▸ LDHA P00338 1/20 0.49
▸ LDHB P07195 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ESR1 P03372 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ JAK2 O60674 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46
▸ CHEK2 O96017 1/20 0.46
▸ PRKCG P05129 1/20 0.46
▸ CDK1 P06493 1/20 0.46
▸ FES P07332 1/20 0.46
▸ RET P07949 1/20 0.46
▸ ROS1 P08922 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3460196 0.96 ATR (0.54) ATRLDHALDHBALDH1A1MEN1
SCHEMBL3461409 0.88 ATR (0.56) ATRLDHALDHBJAK2MAP4K4
SCHEMBL3461585 0.88 ATR (0.56) ATRLDHALDHBJAK2MAP4K4
SCHEMBL3461683 0.88 ATR (0.54) ATRLDHALDHBALDH1A1JAK2
SCHEMBL3461305 0.86 ATR (0.58) ATRLDHALDHBJAK2MAP4K4
SCHEMBL3460265 0.84 ATR (0.51) ATRLDHALDHBPOLBKMT2A
SCHEMBL3461766 0.84 ATR (0.51) ATRLDHALDHBPOLBMAPT
SCHEMBL3460800 0.84 ATR (0.57) ATRLDHALDHBJAK2MAP4K4
SCHEMBL3461752 0.84 ATR (0.51) ATRLDHALDHBMEN1MAPT
SCHEMBL3461970 0.84 ATR (0.56) ATRLDHALDHBJAK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 — — EP claimed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 — — US claimed
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 — — EP disclosed
US-7704995-B2 Protein kinase modulators and methods of use EXELIXIS, INC. (US) 2010-04-27 — — US disclosed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211709-A1 Protein kinase modulators and methods of use GRK2, MAP4K2, MAPKAPK2 ATR 556/4885LDHA 2158/4885LDHB 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback